Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Activation of Integrins01:15

Activation of Integrins

4.3K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
4.3K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

2.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.7K
Integrins01:10

Integrins

4.8K
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
4.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

2.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild-to-moderate psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis.

RMD open·2025
Same author

Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa.

The journal of allergy and clinical immunology. Global·2025
Same author

First-in-Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants.

Clinical pharmacology and therapeutics·2025
Same author

Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis.

Frontiers in pharmacology·2024
Same author

Impact of Diversification on Movement Self-Perception and Movement Performance in University Sports Students.

Research quarterly for exercise and sport·2023

Related Experiment Video

Updated: Apr 28, 2026

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.2K

Small Macrocycles As Highly Active Integrin α2β1 Antagonists.

Nis Halland1, Horst Blum1, Christian Buning1

  • 1Sanofi R&D , Industriepark Höchst Building G838, D-65926 Frankfurt am Main, Germany.

ACS Medicinal Chemistry Letters
|June 6, 2014
PubMed
Summary
This summary is machine-generated.

Researchers developed novel macrocyclic antagonists targeting the platelet collagen receptor α2β1. These potent compounds, with low nanomolar activity, show promising potential for further investigation.

Keywords:
Integrinmacrocyclemetathesisplatelet collagen receptorrestricted conformation

More Related Videos

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors
09:45

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors

Published on: April 27, 2017

10.0K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K

Related Experiment Videos

Last Updated: Apr 28, 2026

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.2K
Modification and Functionalization of the Guanidine Group by Tailor-made Precursors
09:45

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors

Published on: April 27, 2017

10.0K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K

Area of Science:

  • Medicinal Chemistry
  • Biochemistry
  • Pharmacology

Background:

  • Platelet collagen receptor α2β1 plays a crucial role in thrombosis and inflammation.
  • Existing therapies targeting this receptor have limitations.

Purpose of the Study:

  • To develop novel, potent, and selective antagonists of the platelet collagen receptor α2β1.
  • To elucidate the structure-activity relationships and binding mode of these novel antagonists.

Main Methods:

  • Design and synthesis of amino acid-derived macrocyclic compounds.
  • In vitro biochemical assays to determine inhibitory activity (IC50 values) against integrin α2β1.
  • X-ray crystallography to determine the three-dimensional structure of key compounds.
  • Molecular docking studies to predict binding interactions within the α2β1 integrin.

Main Results:

  • A series of 14-18-membered macrocycles were synthesized, showing high activity against integrin α2β1 with IC50s in the low nanomolar range.
  • Macrocycle conformation was critical for activity, as revealed by X-ray crystallography.
  • Docking studies provided insights into key binding features within the metal-ion-dependent adhesion site (MIDAS) of the β1 subunit.
  • Macrocycle 38 emerged as a lead candidate for further preclinical development.

Conclusions:

  • Novel macrocyclic compounds effectively antagonize the platelet collagen receptor α2β1.
  • Structural insights guide the design of potent integrin α2β1 antagonists.
  • Macrocycle 38 represents a promising candidate for further therapeutic development.